[et_pb_section fb_built=”1″ _builder_version=”4.27.4″ _module_preset=”default” background_color=”#1b427d” global_colors_info=”{}”][et_pb_row column_structure=”1_2,1_2″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_2″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”http:\/\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/04\/biocon.jpg” title_text=”biocon” align=”center” force_fullwidth=”on” _builder_version=”4.27.4″ _module_preset=”default” module_alignment=”center” box_shadow_style=”preset1″ global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][et_pb_column type=”1_2″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_text_color=”#FFFFFF” text_orientation=”justified” global_colors_info=”{}”]Biocon Limited, founded in 1978 by Kiran Mazumdar-Shaw, is India\u2019s leading biopharmaceutical company, headquartered in Bengaluru. It focuses on developing affordable, innovative therapeutics for chronic diseases like diabetes, cancer, and autoimmune disorders. Biocon operates through four key segments: Generics (APIs and formulations), Biosimilars (insulin and monoclonal antibodies), Novel Biologics (new molecules), and Research Services (via subsidiary Syngene). Its business model emphasizes a fully integrated value chain, from drug discovery to commercialization, leveraging India\u2019s cost-effective R&D and manufacturing capabilities.<\/p>\n
With a global presence in over 120 countries, Biocon serves markets like the U.S., Europe, and emerging economies, though 86% of its demand comes from developed markets. The company has transitioned from API manufacturing to an innovation-led strategy, focusing on biosimilars and novel biologics to counter pricing pressures in generics. Strategic partnerships (e.g., Mylan, Viatris) and acquisitions (e.g., Viatris\u2019 biosimilars business) have strengthened its global footprint. Biocon\u2019s revenue for FY19 was \u20b956,588 million (USD 871 million), with a market cap of approximately \u20b933,568 crore in 2024. Despite challenges like regulatory complexities and competition, Biocon\u2019s robust pipeline, cost advantage, and focus on health equity position it as a leader in India\u2019s biotech revolution.[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_3,1_3,1_3″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_3″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_social_media_follow icon_color=”#FFFFFF” _builder_version=”4.27.4″ _module_preset=”default” text_orientation=”center” global_colors_info=”{}”][et_pb_social_media_follow_network social_network=”facebook” url=”https:\/\/www.facebook.com\/bioconlimited\/” _builder_version=”4.27.4″ _module_preset=”default” background_color=”#3b5998″ global_colors_info=”{}” follow_button=”off” url_new_window=”on”]facebook[\/et_pb_social_media_follow_network][et_pb_social_media_follow_network social_network=”twitter” url=”https:\/\/x.com\/bioconlimited” _builder_version=”4.27.4″ _module_preset=”default” background_color=”#000000″ global_colors_info=”{}” follow_button=”off” url_new_window=”on”]X[\/et_pb_social_media_follow_network][et_pb_social_media_follow_network social_network=”instagram” url=”https:\/\/www.instagram.com\/biocon_limited\/?hl=en” _builder_version=”4.27.4″ _module_preset=”default” background_color=”#ea2c59″ global_colors_info=”{}” follow_button=”off” url_new_window=”on”]instagram[\/et_pb_social_media_follow_network][et_pb_social_media_follow_network social_network=”youtube” url=”https:\/\/www.youtube.com\/bioconlimited” _builder_version=”4.27.4″ _module_preset=”default” background_color=”#a82400″ global_colors_info=”{}” follow_button=”off” url_new_window=”on”]youtube[\/et_pb_social_media_follow_network][et_pb_social_media_follow_network social_network=”linkedin” url=”https:\/\/www.linkedin.com\/company\/biocon\/” _builder_version=”4.27.4″ _module_preset=”default” background_color=”#007bb6″ global_colors_info=”{}” follow_button=”off” url_new_window=”on”]linkedin[\/et_pb_social_media_follow_network][\/et_pb_social_media_follow][\/et_pb_column][et_pb_column type=”1_3″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_button button_url=”https:\/\/www.biocon.com\/” url_new_window=”on” button_text=”Official Website” button_alignment=”center” _builder_version=”4.27.4″ _module_preset=”default” custom_button=”on” button_text_color=”#FFFFFF” global_colors_info=”{}”][\/et_pb_button][\/et_pb_column][et_pb_column type=”1_3″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_button button_url=”https:\/\/www.biocon.com\/investor-relations\/financial-information\/annual-reports\/” url_new_window=”on” button_text=”Financial Reports” button_alignment=”center” _builder_version=”4.27.4″ _module_preset=”default” custom_button=”on” button_text_color=”#FFFFFF” global_colors_info=”{}”][\/et_pb_button][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.27.4″ _module_preset=”default” custom_padding=”14px||12px|||” global_colors_info=”{}”][et_pb_row _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_code _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”]